Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Evidence: Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan

Official URL: https://fevir.net/resources/Evidence/397478 Version: 1.0.0-ballot3
Standards status: Informative Computable Name: Evidence_for_Results_for_Adverse_event_free_and_hypertension_control_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan
Other Identifiers: FEvIR Object Identifier: FEvIR Object Identifier#397478, OID:2.16.840.1.113883.4.642.40.44.22.71

Copyright/Legal: https://creativecommons.org/licenses/by-nc-sa/4.0/

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

Title: Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan

Variable in role of population: the study group

Variable in role of exposure: GroupAssignment: Quadpill vs. Candesartan

Variable in role of outcome: Adverse event free and hypertension control at 12 weeks

Statistic: odds ratio (coded as: STATO:0000182 from https://fevir.net/sevco) 0.83